PURPOSE: To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted. METHOD: Participants received 250-mg self-emulsifying drug delivery system (SEDDS) capsules of TPV at doses between 250 mg and 1250 mg twice daily for 11 days, then received one or two RTV 100-mg SEDDS capsules, in addition to the TPV capsules, for the next 21 days. RESULTS: Coadministration of TPV and RTV (TPV/r) resulted in a greater than 20-fold increase in steady-state TPV trough concentrations (Cssmin) as compared with TPV at steady state alone. Mean TPV Cssmin was above a preliminary target threshold of 20 microM with all but one of the RTV-boosted doses; without boosting, none of the TPV-alone doses exceeded the threshold. The average steady-state Cssmin for TPV 500 mg and 750 mg with RTV 100 mg or 200 mg were 20 to 57 times the protein-adjusted TPV IC90R49\CCR418569) for protease inhibitor-resistant HIV-1. An erythromycin breath test, a surrogate marker for cytochrome P450 isoenzyme 3A4 activity, indicated that all TPV/r combinations given provided net inhibition of this isoenzyme. The most frequent treatment-related adverse events were mild gastrointestinal symptoms. CONCLUSION: This phase 1 study demonstrated that RTV-boosted TPV achieves concentrations that are expected to be effective in treating drug-experienced patients.
RCT Entities:
PURPOSE: To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted. METHOD:Participants received 250-mg self-emulsifying drug delivery system (SEDDS) capsules of TPV at doses between 250 mg and 1250 mg twice daily for 11 days, then received one or two RTV 100-mg SEDDS capsules, in addition to the TPV capsules, for the next 21 days. RESULTS: Coadministration of TPV and RTV (TPV/r) resulted in a greater than 20-fold increase in steady-state TPV trough concentrations (Cssmin) as compared with TPV at steady state alone. Mean TPV Cssmin was above a preliminary target threshold of 20 microM with all but one of the RTV-boosted doses; without boosting, none of the TPV-alone doses exceeded the threshold. The average steady-state Cssmin for TPV 500 mg and 750 mg with RTV 100 mg or 200 mg were 20 to 57 times the protein-adjusted TPV IC90R49\CCR418569) for protease inhibitor-resistant HIV-1. An erythromycin breath test, a surrogate marker for cytochrome P450 isoenzyme 3A4 activity, indicated that all TPV/r combinations given provided net inhibition of this isoenzyme. The most frequent treatment-related adverse events were mild gastrointestinal symptoms. CONCLUSION: This phase 1 study demonstrated that RTV-boosted TPV achieves concentrations that are expected to be effective in treating drug-experienced patients.
Authors: Geoffrey Mukwaya; Thomas MacGregor; David Hoelscher; Thomas Heming; Daniel Legg; Kelli Kavanaugh; Phillip Johnson; John P Sabo; Scott McCallister Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191
Authors: P A Pham; C J L la Porte; L S Lee; R van Heeswijk; J P Sabo; M M Elgadi; P J Piliero; P Barditch-Crovo; E Fuchs; C Flexner; D W Cameron Journal: Antimicrob Agents Chemother Date: 2009-08-10 Impact factor: 5.191
Authors: Daniel Gonzalez de Requena; Stefano Bonora; Andrea Calcagno; Antonio D'Avolio; Marco Siccardi; Silvia Fontana; Maria Grazia Milia; Mauro Sciandra; Silvia Garazzino; Antonio Di Garbo; Lorena Baietto; Laura Trentini; Giovanni Di Perri Journal: Antimicrob Agents Chemother Date: 2007-12-26 Impact factor: 5.191
Authors: Linzhi Chen; John P Sabo; Elsy Philip; Yanping Mao; Stephen H Norris; Thomas R MacGregor; Jan M Wruck; Sandra Garfinkel; Mark Castles; Amy Brinkman; Hernan Valdez Journal: Antimicrob Agents Chemother Date: 2007-05-07 Impact factor: 5.191